teriparatide Side Effects
Also known as: Forteo
Analysis of 111,257 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
111,257
Death-Related
5,261
4.7% of reports
Hospitalizations
23,997
21.6% of reports
Top Indication
Osteoporosis
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 5,261 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 2,901 |
| PNEUMONIA | 401 |
| FALL | 263 |
| MYOCARDIAL INFARCTION | 192 |
| DYSPNOEA | 162 |
| CEREBROVASCULAR ACCIDENT | 161 |
| RENAL FAILURE | 160 |
| RESPIRATORY FAILURE | 155 |
| CARDIAC ARREST | 149 |
| ASTHENIA | 139 |
| CARDIAC FAILURE | 139 |
| HOSPITALISATION | 135 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 134 |
| MALAISE | 126 |
| CARDIAC FAILURE CONGESTIVE | 114 |
| CARDIAC DISORDER | 111 |
| SEPSIS | 111 |
| PAIN | 107 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 102 |
| NAUSEA | 91 |
Reactions in Hospitalization Reports
Top reactions in 23,997 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FALL | 3,935 |
| PNEUMONIA | 1,575 |
| HOSPITALISATION | 1,503 |
| ASTHENIA | 1,397 |
| PAIN | 1,383 |
| MALAISE | 1,349 |
| BACK PAIN | 1,318 |
| NAUSEA | 1,299 |
| DIZZINESS | 1,192 |
| PAIN IN EXTREMITY | 1,127 |
| PHARMACEUTICAL PRODUCT COMPLAINT | 1,120 |
| DYSPNOEA | 1,106 |
| FATIGUE | 1,049 |
| ARTHRALGIA | 1,029 |
| HIP FRACTURE | 934 |
| VOMITING | 854 |
| GAIT DISTURBANCE | 726 |
| DIARRHOEA | 702 |
| HEADACHE | 694 |
| WEIGHT DECREASED | 677 |
Nearby — Related Medications
What the FAERS Data Reveals About teriparatide Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 111,257 voluntary reports linked to teriparatide and its brand equivalents (Forteo), spanning 2004 through 2025. Of those, 5,261 (4.7%) listed death as an outcome and 23,997 (21.6%) involved hospitalization. The most common indication reported alongside adverse events was Osteoporosis.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 91% were female and 9% male; age distribution skews toward 75+, with 25,089 reports in that bracket. The single most reported reaction is nausea with 8,956 submissions, followed by arthralgia and pain in extremity.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.